Glenmark Life Sciences Ltd

GLS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,347 cr, stock is ranked 468
Low RiskStock is 1.69x as volatile as Nifty
440.954.55 (+1.04%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,347 cr, stock is ranked 468
Low RiskStock is 1.69x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
12.77
PB RatioPB Ratio
7.10
Dividend YieldDiv. Yield
4.23%
Sector PESector PE
34.39
Sector PBSector PB
4.70
Sector Div YldSctr Div Yld
0.78%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.

Investor PresentationView older 

Apr 20, 2022

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20192020202120220.891.551.892.140.200.310.350.42
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Monitoring Agency Report 
Announced OnMay 13, 2022

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 31st March, 2022 in respect of utilization of proceeds of the IPO of the Company. | Download

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 31st March, 2022 in respect of utilization of proceeds of the IPO of the Company. | Download

Recording of Analysts/Institutional Investor Meet/Con. Call 
Announced OnApr 22, 2022

Pursuant to Regulation 30 and 46 read with clause 15 of Para A of Part A of Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that we have uploaded audio recording of the Q4 & FY22 Earnings Call held on April 21, 2022, on our investor website : https://www.glenmarklifesciences.com/financial-results.php under Financial Results.We request you to take note and host the same on your website. | Download

Pursuant to Regulation 30 and 46 read with clause 15 of Para A of Part A of Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that we have uploaded audio recording of the Q4 & FY22 Earnings Call held on April 21, 2022, on our investor website : https://www.glenmarklifesciences.com/financial-results.php under Financial Results.We request you to take note and host the same on your website. | Download

Cash Dividend 
Ex. DateNov 22, 2021

Interim • Div/Share: ₹ 10.5

See all events